These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 10389145)

  • 61. Neurosteroids modulate compulsive and persistent behavior in rodents: implications for obsessive-compulsive disorder.
    S N U; J M V; N S J; P V D
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Oct; 33(7):1161-6. PubMed ID: 19549549
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Pharmacology of quinpirole-stimulated [35S]GTPgammaS binding: discrepancy with receptor binding profile.
    Gilliland SL; Alper RH; Levant B
    Eur J Pharmacol; 2000 Mar; 392(3):125-8. PubMed ID: 10762663
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Quinpirole-induced sensitization to noisy/sparse periodic input: temporal synchronization as a component of obsessive-compulsive disorder.
    Gu BM; Cheng RK; Yin B; Meck WH
    Neuroscience; 2011 Apr; 179():143-50. PubMed ID: 21284954
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Behavioural response to SKF 38393 and quinpirole following chronic antidepressant treatment.
    Allison K; Ivanová S; Greenshaw AJ
    Eur J Pharmacol; 1995 Apr; 277(2-3):139-44. PubMed ID: 7493601
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A selective serotonin reuptake inhibitor ameliorates obsessive-compulsive disorder-like perseverative behavior by attenuating 5-HT
    Hatakama H; Asaoka N; Nagayasu K; Shirakawa H; Kaneko S
    Neuropharmacology; 2022 Mar; 206():108926. PubMed ID: 34921828
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
    Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
    Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Animal models of obsessive compulsive disorder: recent findings and future directions.
    Hoffman KL
    Expert Opin Drug Discov; 2011 Jul; 6(7):725-37. PubMed ID: 22650979
    [TBL] [Abstract][Full Text] [Related]  

  • 68. An Adenosine A
    Asaoka N; Nishitani N; Kinoshita H; Nagai Y; Hatakama H; Nagayasu K; Shirakawa H; Nakagawa T; Kaneko S
    eNeuro; 2019; 6(1):. PubMed ID: 30834304
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Modulation of [3H]quinpirole binding at striatal D2 dopamine receptors by a monoamine oxidaseA-like site: evidence from radioligand binding studies and D2 receptor- and MAO(A)-deficient mice.
    Levant B; Morgan KA; Ahlgren-Beckendorf JA; Grandy DK; Chen K; Shih JC; Seif I
    Life Sci; 2001 Nov; 70(2):229-41. PubMed ID: 11787947
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Neuroreceptor kinetics in rats repeatedly exposed to quinpirole as a model for OCD.
    Servaes S; Glorie D; Stroobants S; Staelens S
    PLoS One; 2019; 14(3):e0213313. PubMed ID: 30845202
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effects of monoamine oxidase inhibitors and dopamine agonists on the behavior of mammal- and frog-eating snakes.
    Temple JG; Barthalmus GT
    Physiol Behav; 1994 May; 55(5):927-33. PubMed ID: 7912837
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Neurobiology and clinical pharmacology of obsessive-compulsive disorder.
    Micallef J; Blin O
    Clin Neuropharmacol; 2001; 24(4):191-207. PubMed ID: 11479390
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The pharmacotherapy of obsessive-compulsive disorder.
    McDougle CJ; Goodman WK; Price LH
    Pharmacopsychiatry; 1993 May; 26 Suppl 1():24-9. PubMed ID: 8378419
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Diversity of obsessive-compulsive disorder and pharmacotherapy associated with obsessive-compulsive spectrum disorders].
    Nakamae T
    Seishin Shinkeigaku Zasshi; 2011; 113(10):1016-25. PubMed ID: 22187889
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Obsessive-compulsive disorder: Insights from animal models.
    Szechtman H; Ahmari SE; Beninger RJ; Eilam D; Harvey BH; Edemann-Callesen H; Winter C
    Neurosci Biobehav Rev; 2017 May; 76(Pt B):254-279. PubMed ID: 27168347
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Features of compulsive checking behavior mediated by nucleus accumbens and orbital frontal cortex.
    Dvorkin A; Silva C; McMurran T; Bisnaire L; Foster J; Szechtman H
    Eur J Neurosci; 2010 Nov; 32(9):1552-63. PubMed ID: 20731708
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Animal behavior as a conceptual framework for the study of obsessive-compulsive disorder (OCD).
    Eilam D; Zor R; Fineberg N; Hermesh H
    Behav Brain Res; 2012 Jun; 231(2):289-96. PubMed ID: 21763354
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: A critical review.
    Dell'Osso B; Nestadt G; Allen A; Hollander E
    J Clin Psychiatry; 2006 Apr; 67(4):600-10. PubMed ID: 16669725
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Enhanced reward-facilitating effects of d-amphetamine in rats in the quinpirole model of obsessive-compulsive disorder.
    Schmidt TT; Rea E; Shababi-Klein J; Panagis G; Winter C
    Int J Neuropsychopharmacol; 2013 Jun; 16(5):1083-91. PubMed ID: 23043789
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Ritualistic chewing behavior induced by mCPP in the rat is an animal model of obsessive compulsive disorder.
    Kreiss DS; Coffman CF; Fiacco NR; Granger JC; Helton BM; Jackson JC; Kim LV; Mistry RS; Mizer TM; Palmer LV; Vacca JA; Winkler SS; Zimmer BA
    Pharmacol Biochem Behav; 2013 Mar; 104():119-24. PubMed ID: 23333679
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.